Academician
BEGÜM GÜNEŞ
Doktor Öğretim Üyesi
Citation impact
OpenAlex YÖKSİS articles matched in OpenAlex: 4 + YÖKSİS · co-author record: 10
h-index
4
Percentile in Türkiye: 28
#225 of 349 at their university by h-index
- i10-index
- 2
- Total citations
- 58 Top 73% in Türkiye
- Per article
- 4.1
- FWCI
- 0.59 1.00 = world average
- World top 1%
- 0
- World top 10%
- 0
Most cited articles
- Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS‐CoV ‐2 outbreak in Turkey and what happened to them?
- Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center
- Challenges and practices arising during public health emergencies: A qualitative survey on ethics committees
How is this computed?
h-index and citations are computed from the citation counts of this academic’s YÖKSİS articles matched in OpenAlex (not Google Scholar, WoS or Scopus). Unmatched articles are not included. 10 articles (50 citations) tagged with this academic’s YÖK author id in co-authors’ YÖKSİS records count only towards citations, h-index and i10; article counts, percentiles and rankings use their own YÖKSİS list. h-index on the OpenAlex author profile: 4.
Indexes and citation percentiles
?Top 1%0
Top 10%0
Avg · n 4
%51.6
Other counts
Scopus (SJR)
- YÖKSİS rows 3
WoS (JCR)
- YÖKSİS rows 3
Articles
Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.
Journals with publications
4 journals
Narrow down
Article list
- 2025 The Efficacy, Safety and Longevity of Biologic Treatments in Pediatric and Adult Psoriasis Patients: A Comparative Multi-Center, Real-Life Study YÖKSİS SJR Q3 JCR Q3 OpenAlex 66.0%
- 2025 Frequency of tuberculosis in psoriasis patients using anti-TNF therapy during 16 years of follow-up YÖKSİS SJR Q2 JCR Q3 OpenAlex 68.5%
- 2024 Reliability and Sensitivity of a New Simple Screening Test (TUPAST) in Psoriatic Arthritis Including Axial Involvement: Methodological Study YÖKSİS OpenAlex 19.2%
- 2023 Comparison of Survival and Retention Rates between Infliximab and Adalimumab for Psoriasis: 10-year Experience at a Single Tertiary Center YÖKSİS SJR Q1 JCR Q2 OpenAlex 52.8%